Geneva Capital Management LLC Lowers Stake in Repligen Co. (NASDAQ:RGEN)

Geneva Capital Management LLC reduced its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 135,585 shares of the biotechnology company's stock after selling 3,092 shares during the period. Geneva Capital Management LLC owned about 0.24% of Repligen worth $19,516,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Champlain Investment Partners LLC grew its holdings in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock worth $211,464,000 after buying an additional 850,345 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Repligen in the fourth quarter valued at about $52,492,000. Allspring Global Investments Holdings LLC grew its position in shares of Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after acquiring an additional 203,011 shares during the period. DF Dent & Co. Inc. increased its stake in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after purchasing an additional 139,615 shares during the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of Repligen by 421.9% during the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company's stock worth $18,796,000 after purchasing an additional 102,100 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Repligen Price Performance

NASDAQ RGEN traded down $18.71 on Monday, hitting $136.99. The stock had a trading volume of 1,516,633 shares, compared to its average volume of 639,476. The firm has a 50-day moving average of $157.23 and a 200-day moving average of $148.59. The company has a market capitalization of $7.68 billion, a price-to-earnings ratio of -268.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $200.23.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Equities analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of recent research reports. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. StockNews.com lowered Repligen from a "hold" rating to a "sell" rating in a report on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Royal Bank of Canada lifted their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $181.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.